Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
November 16 2021 - 6:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒
Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
|
For
Period Ended: September 30, 2021
|
|
|
|
☐
Transition Report on Form 10-K
|
|
|
|
☐
Transition Report on Form 20-F
|
|
|
|
☐
Transition Report on Form 11-K
|
|
|
|
☐
Transition Report on Form 10-Q
|
|
|
|
☐
Transition Report on Form N-SAR
|
|
|
|
For
the Transition Period Ended: ______________________
|
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _________________________________
PART
I - REGISTRANT INFORMATION
MusclePharm
Corporation
|
Full Name of Registrant
|
|
|
Former Name if Applicable
|
|
3753
Howard Hughes Parkway, Ste 200-849
|
Address of Principal Executive
Office (Street and Number)
|
|
Las
Vegas, NV 89169
|
City, State and Zip Code
|
PART
II - RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
☒
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25 has been attached if applicable.
|
PART
III - NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
The
Company was unable to compile the necessary financial information required to prepare a complete filing, in part due to the Company’s
transition to a new Chief Financial Officer and turnover within the Company’s accounting department. Thus, the Company would be
unable to file the quarterly report in a timely manner without unreasonable effort or expense. The Company expects to file the quarterly
report within the extension period.
PART
IV - OTHER INFORMATION
(1)
|
Name and telephone
number of the person to contact in regard to this notification
|
Sabina
Rizvi
|
|
(800)
|
|
292-3909
|
(Name)
|
|
(Area Code)
|
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange
Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed?
If answer is no, identify report(s).
☒
Yes ☐ No
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
MusclePharm
Corporation
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November
15, 2021
|
By:
|
/s/
Sabina Rizvi
|
|
|
Sabina Rizvi
|
|
|
President and Chief Financial
Officer
|
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jul 2023 to Jul 2024